查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541189

2024-2032 年非黑色素瘤皮膚癌治療市場報告（依治療類型、適應症、最終用途和地區）

Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球非黑色素瘤皮膚癌治療市場規模達5.632億美元。

非黑色素瘤皮膚癌（NMSC）是指皮膚上層惡性細胞的異常生長。 NMSC 的一些常見類型包括基底細胞癌、默克爾細胞癌和鱗狀細胞癌以及皮膚 T 細胞淋巴瘤。它的主要特徵是皮膚上出現堅硬的腫塊或鱗狀斑塊。治療方法包括透過外科手術去除癌細胞，包括顯微手術、雷射療法和冷凍療法，以及各種非手術治療，例如光動力療法（PDT）、放射療法和電療法。

全球皮膚癌盛行率的增加和老年人口的增加是推動市場成長的關鍵因素。此外，大眾對 NMSC 可用治療替代方案的認知不斷提高也刺激了市場成長。與傳統使用的療法相比，淺層放射療法減少了對患者身體的副作用，並且可以透過創新的攜帶式設備進行。這些設備也用於高精度和高靈敏度的皮膚病變的早期診斷。此外，各種技術進步，例如電子近距離放射治療（eBx）的發展，也是其他生長誘導因素。 eBx 是一種無痛、非侵入性的標靶低能量放射治療，需要更短的治療療程，並將附近健康組織的輻射暴露風險降至最低。其他因素，包括個人醫療保健支出的增加和政府對臨床試驗的資助，以及廣泛的研發（R＆D）活動，預計將進一步推動市場。

本報告回答的關鍵問題：

  • 迄今為止，全球非黑色素瘤皮膚癌治療市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球非黑色素瘤皮膚癌治療市場有何影響？
  • 主要區域市場有哪些？
  • 根據治療類型的市場分類是怎樣的？
  • 根據指示，市場的細分是什麼？
  • 根據最終用途分類的市場是怎樣的？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球非黑色素瘤皮膚癌治療市場的結構如何？
  • 產業競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球非黑色素瘤皮膚癌治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依治療類型

  • 化療
    • 市場趨勢
    • 市場預測
  • 放射治療
    • 市場趨勢
    • 市場預測
  • 光動力療法
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依跡象

  • 基底細胞癌
    • 市場趨勢
    • 市場預測
  • T細胞淋巴瘤
    • 市場趨勢
    • 市場預測
  • 鱗狀細胞癌
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：最終用途別

  • 醫院
    • 市場趨勢
    • 市場預測
  • 專科診所
    • 市場趨勢
    • 市場預測
  • 門診手術中心
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Accuray Incorporated
    • Almirall SA
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Elekta AB
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Icad Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Varian Medical Systems Inc.
Product Code: SR112024A3438

The global non-melanoma skin cancer treatment market size reached US$ 563.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 850.1 Million by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.

Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-melanoma skin cancer treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, indication and end use.

Breakup by Treatment Type:

Chemotherapy

Radiation Therapy

Photodynamic Therapy

Others

Breakup by Indication:

Basal Cell Carcinoma

T-Cell Lymphoma

Squamous Cell Carcinoma

Others

Breakup by End Use:

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.

Key Questions Answered in This Report:

  • How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Melanoma Skin Cancer Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Photodynamic Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Basal Cell Carcinoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 T-Cell Lymphoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Squamous Cell Carcinoma
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Accuray Incorporated
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Almirall S.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Elekta AB
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Eli Lilly and Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Icad Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sun Pharmaceutical Industries Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Varian Medical Systems Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Non-Melanoma Skin Cancer Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by End Use (in %), 2023
  • Figure 6: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 8: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Non-Melanoma Skin Cancer Treatment Industry: SWOT Analysis
  • Figure 82: Global: Non-Melanoma Skin Cancer Treatment Industry: Value Chain Analysis
  • Figure 83: Global: Non-Melanoma Skin Cancer Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Melanoma Skin Cancer Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 5: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Non-Melanoma Skin Cancer Treatment Market Structure
  • Table 7: Global: Non-Melanoma Skin Cancer Treatment Market: Key Players